The price of Ekso Bionics Holdings Inc (NASDAQ: EKSO) closed at $1.36 in the last session, down -4.23% from day before closing price of $1.42. In other words, the price has decreased by -$0.0600 from its previous closing price. On the day, 357021 shares were traded.
Ratios:
We take a closer look at EKSO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.87 and its Current Ratio is at 2.49. In the meantime, Its Debt-to-Equity ratio is 0.57 whereas as Long-Term Debt/Eq ratio is at 0.44.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 02 ’23 when Lathan Corinna bought 4,032 shares for $1.24 per share. The transaction valued at 5,005 led to the insider holds 147,990 shares of the business.
Lathan Corinna bought 5,500 shares of EKSO for $5,222 on Aug 23 ’23. The Director now owns 143,958 shares after completing the transaction at $0.95 per share. On Aug 17 ’23, another insider, Davis Scott G., who serves as the President & COO of the company, sold 37,446 shares for $1.00 each. As a result, the insider received 37,281 and left with 331,372 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EKSO now has a Market Capitalization of 24.44M and an Enterprise Value of 22.97M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.33 while its Price-to-Book (P/B) ratio in mrq is 1.60. Its current Enterprise Value per Revenue stands at 1.26 whereas that against EBITDA is -1.74.
Stock Price History:
The Beta on a monthly basis for EKSO is 1.62, which has changed by -17.58% over the last 52 weeks, in comparison to a change of 27.86% over the same period for the S&P500. Over the past 52 weeks, EKSO has reached a high of $3.13, while it has fallen to a 52-week low of $0.62. The 50-Day Moving Average of the stock is 1.8514, while the 200-Day Moving Average is calculated to be 1.4054.
Shares Statistics:
According to the various share statistics, EKSO traded on average about 219.69K shares per day over the past 3-months and 115.51k shares per day over the past 10 days. A total of 17.90M shares are outstanding, with a floating share count of 15.28M. Insiders hold about 14.63% of the company’s shares, while institutions hold 7.96% stake in the company. Shares short for EKSO as of Mar 15, 2024 were 111.22k with a Short Ratio of 0.51, compared to 172.14k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.62% and a Short% of Float of 0.65%.
Earnings Estimates
The company has 1 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.16 for the current quarter, with a high estimate of -$0.16 and a low estimate of -$0.16, while EPS last year was -$0.33. The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.13 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.49 and -$0.49 for the fiscal current year, implying an average EPS of -$0.49. EPS for the following year is -$0.24, with 1 analysts recommending between -$0.24 and -$0.24.
Revenue Estimates
According to 1 analysts, the current quarter’s revenue is expected to be $4.99M. It ranges from a high estimate of $4.99M to a low estimate of $4.99M. As of the current estimate, Ekso Bionics Holdings Inc’s year-ago sales were $4.12M, an estimated increase of 21.10% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $5.88M, an increase of 35.20% over than the figure of $21.10% in the same quarter last year. There is a high estimate of $5.88M for the next quarter, whereas the lowest estimate is $5.88M.
A total of 1 analysts have provided revenue estimates for EKSO’s current fiscal year. The highest revenue estimate was $23.5M, while the lowest revenue estimate was $23.5M, resulting in an average revenue estimate of $23.5M. In the same quarter a year ago, actual revenue was $18.28M, up 28.60% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $30.5M in the next fiscal year. The high estimate is $30.5M and the low estimate is $30.5M. The average revenue growth estimate for next year is up 29.80% from the average revenue estimate for this year.
